1 |
TNFRSF13C
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Human T-cell leukemia virus 1 infection, Primary immunodeficiency | D12151
D12151
|
Ianalumab
| 5件: 35 35, 46, 49, 53, 95 |
2 |
CSF3R
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03235
D03235
|
Filgrastim
| 34件: 2 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
3 |
DHFR
| 5件: One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142
D00142
|
Methotrexate
| 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
4 |
DHFR
| 5件: One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D02115
D02115
|
Methotrexate
| 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
5 |
DHFR2
| 5件: One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142
D00142
|
Methotrexate
| 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
6 |
DHFR2
| 5件: One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D02115
D02115
|
Methotrexate
| 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
7 |
FCGRT
| - | D11876
D11876
|
Efgartigimod alfa
| 2件: 35 35, 63 |
8 |
MTOR
| 51件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D00753
D00753
|
Sirolimus
| 41件: 2 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
9 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D01441
D01441
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
10 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D08066
D08066
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
11 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00292
D00292
|
Dexamethasone
| 21件: 35 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
12 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00385
D00385
|
Triamcinolone
| 10件: 35 35, 46, 56, 70, 90, 96, 107, 162, 226, 298 |
13 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00407
D00407
|
Methylprednisolone
| 39件: 35 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
14 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00472
D00472
|
Prednisolone
| 37件: 35 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
15 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00473
D00473
|
Prednisone
| 41件: 35 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
16 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00751
D00751
|
Methylprednisolone
| 39件: 35 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
17 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00975
D00975
|
Dexamethasone
| 21件: 35 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
18 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00979
D00979
|
Methylprednisolone
| 39件: 35 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
19 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00980
D00980
|
Prednisolone
| 37件: 35 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
20 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00981
D00981
|
Prednisolone
| 37件: 35 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
21 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00982
D00982
|
Prednisolone
| 37件: 35 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
22 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00983
D00983
|
Triamcinolone
| 10件: 35 35, 46, 56, 70, 90, 96, 107, 162, 226, 298 |
23 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00984
D00984
|
Triamcinolone
| 10件: 35 35, 46, 56, 70, 90, 96, 107, 162, 226, 298 |
24 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00985
D00985
|
Triamcinolone
| 10件: 35 35, 46, 56, 70, 90, 96, 107, 162, 226, 298 |
25 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01239
D01239
|
Prednisolone
| 37件: 35 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
26 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01510
D01510
|
Dexamethasone
| 21件: 35 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
27 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01615
D01615
|
Dexamethasone
| 21件: 35 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
28 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01632
D01632
|
Dexamethasone
| 21件: 35 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
29 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01948
D01948
|
Dexamethasone
| 21件: 35 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
30 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01998
D01998
|
Prednisolone
| 37件: 35 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
31 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02156
D02156
|
Prednisolone
| 37件: 35 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
32 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02174
D02174
|
Dexamethasone
| 21件: 35 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
33 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02591
D02591
|
Dexamethasone
| 21件: 35 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
34 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02592
D02592
|
Dexamethasone
| 21件: 35 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
35 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03301
D03301
|
Prednisolone
| 37件: 35 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
36 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05000
D05000
|
Methylprednisolone
| 39件: 35 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
37 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05001
D05001
|
Methylprednisolone
| 39件: 35 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
38 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05002
D05002
|
Methylprednisolone
| 39件: 35 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
39 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D06216
D06216
|
Triamcinolone
| 10件: 35 35, 46, 56, 70, 90, 96, 107, 162, 226, 298 |
40 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D08416
D08416
|
Prednisone acetate
| 7件: 35 35, 40, 41, 46, 49, 162, 224 |
41 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00664
D00664
|
Cetirizine
| 4件: 13 13, 28, 35, 300 |
42 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D07662
D07662
|
Cetirizine
| 4件: 13 13, 28, 35, 300 |
43 |
IL2RA
| 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | D00748
D00748
|
Aldesleukin
| 6件: 2 2, 35, 49, 65, 96, 97 |
44 |
IL2RB
| 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer | D00748
D00748
|
Aldesleukin
| 6件: 2 2, 35, 49, 65, 96, 97 |
45 |
IL2RG
| 12件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Inflammatory bowel disease, Primary immunodeficiency | D00748
D00748
|
Aldesleukin
| 6件: 2 2, 35, 49, 65, 96, 97 |
46 |
IMPDH1
| 3件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D00752
D00752
|
Mycophenolate mofetil
| 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
47 |
IMPDH1
| 3件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05094
D05094
|
Mycophenolate mofetil
| 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
48 |
IMPDH1
| 3件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05095
D05095
|
Mycophenolate mofetil
| 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
49 |
IMPDH1
| 3件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05096
D05096
|
Mycophenolic acid
| 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
50 |
IMPDH2
| 3件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D00752
D00752
|
Mycophenolate mofetil
| 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
51 |
IMPDH2
| 3件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05094
D05094
|
Mycophenolate mofetil
| 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
52 |
IMPDH2
| 3件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05095
D05095
|
Mycophenolate mofetil
| 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
53 |
IMPDH2
| 3件: Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways | D05096
D05096
|
Mycophenolic acid
| 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
54 |
KIT
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D01441
D01441
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
55 |
KIT
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D08066
D08066
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
56 |
LTA
| 7件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection | D00742
D00742
|
Etanercept
| 17件: 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298 |
57 |
PDGFRA
| 20件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D01441
D01441
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
58 |
PDGFRA
| 20件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D08066
D08066
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
59 |
PGR
| 5件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer | D00951
D00951
|
Medroxyprogesterone acetate
| 6件: 13 13, 35, 46, 49, 51, 60 |
60 |
PGR
| 5件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer | D08166
D08166
|
Medroxyprogesterone acetate
| 6件: 13 13, 35, 46, 49, 51, 60 |
61 |
PIK3CD
| 106件: Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Apoptosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Cholinergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, GnRH secretion, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Aldosterone-regulated sodium reabsorption, Carbohydrate digestion and absorption, Alzheimer disease, Spinocerebellar ataxia, Prion disease, Bacterial invasion of epithelial cells, Shigellosis, Salmonella infection, Yersinia infection, Chagas disease, Amoebiasis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Acute myeloid leukemia, Small cell lung cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D11437
D11437
|
Parsaclisib
| 3件: 35 35, 53, 61 |
62 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00217
D00217
|
Acetaminophen
| 18件: 3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 |
63 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00217
D00217
|
Acetaminophen
| 18件: 3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 |
64 |
TNF
| 67件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D00742
D00742
|
Etanercept
| 17件: 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298 |
65 |
TNF
| 67件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02598
D02598
|
Infliximab
| 27件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
66 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D02994
D02994
|
Rituximab
| 43件: 35 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
67 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D09314
D09314
|
Ofatumumab
| 2件: 35 35, 46 |